The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 16, 2020

Filed:

May. 06, 2015
Applicants:

The Johns Hopkins University, Baltimore, MD (US);

Northwestern University, Evanston, IL (US);

Inventors:

Sangeeta Ray, Ellicott City, MD (US);

Martin G. Pomper, Baltimore, MD (US);

Thomas J. Meade, Evanston, IL (US);

Ronnie C. Mease, Fairfax, VA (US);

Ying Chen, Timmonium, MD (US);

Xing Yang, Baltimore, MD (US);

Matthew Rotz, Carlsbad, CA (US);

Assignees:

THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US);

NORTHWESTERN UNIVERSITY, Evanston, IL (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 51/00 (2006.01); A61M 36/14 (2006.01); C07D 257/02 (2006.01); A61K 49/10 (2006.01); A61K 51/04 (2006.01); C07D 403/14 (2006.01); A61K 49/12 (2006.01); A61K 51/06 (2006.01); A61K 49/00 (2006.01);
U.S. Cl.
CPC ...
C07D 257/02 (2013.01); A61K 49/0002 (2013.01); A61K 49/106 (2013.01); A61K 49/12 (2013.01); A61K 51/0402 (2013.01); A61K 51/0482 (2013.01); A61K 51/0497 (2013.01); A61K 51/06 (2013.01); C07D 403/14 (2013.01); A61K 49/108 (2013.01);
Abstract

Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.


Find Patent Forward Citations

Loading…